Search
Displaying 311–320 of 612 for “retinal diseases”
-
SalioGen Developing Novel Gene Insertion Therapy for Stargardt Disease
Research NewsThe company’s innovative Gene Coding™ platform enables seamless insertion of DNA into selective genomic locations.
-
Beacon Stories
Adopted into a musical family, Miles Hoyt picked up a guitar at just four years old, and he hasn’t stopped playing since. Now Miles, who has Stargardt disease, and his parents are using music to bring their community together to raise funds for blinding diseases with their Raising Our Sights fundraiser, Smiles for Miles.
-
PYC Doses First Patient in Clinical Trial of RNA Therapy for RP11 (PRPF31 Mutations)
Research NewsThe emerging RNA therapy is designed to boost expression of the PRPF31 protein
-
Beyond Labels: The Inspiring Journey of a Refsum Disease Advocate
Beacon StoriesAfter years of seeking answers, Alan Gunzburg was formally diagnosed with Refsum disease, a rare genetic disorder. Drawing on his unique journey, Alan sheds light on the obstacles he’s faced and how his experience motivated him to make a positive impact in the lives of others.
-
SparingVision Receives Authorization to Launch US Clinical Trial for its Cone-Preserving Treatment
Research NewsThe emerging therapy is designed to work independent of the mutated gene causing retinitis pigmentosa
-
AGTC’s XLRP Gene Therapy Performs Well in Extension of Phase 2 Clinical Trial
Research NewsThe three-month results support the planned launch of the company’s Phase 2/3 Vista trial
-
AGTC Plans Further Clinical Development of Achromatopsia (CNGB3) Gene Therapy
Research NewsInterim results for pediatric patients with CNGB3 mutations were encouraging
-
ReNeuron Not Continuing Clinical Development of Cell-Based Therapy for RP
Research NewsCompany seeks to out-license its retinal progenitor therapy to a partner
-
Nanoscope Therapeutics Launches Phase 2b Clinical Trial for Optogenetic Therapy
Research NewsWhile the trial is for people with RP, the company hopes it will also benefit people with other retinal degenerative diseases
-
AGTC Continues to Report Encouraging Data from its Phase 1/2 XLRP Gene Therapy Clinical Trial
Research NewsThe company is planning the launch of a Phase 2/3 trial for its XLRP gene therapy
.png)
.png)
